Key pathways frequently dysregulated in NSCLC include the epidermal growth factor receptor (EGFR) signaling pathway, which promotes cellular proliferation and survival [9], and the KRAS pathway, which is linked to resistance to targeted therapies [10]. Here, EGFR is linked to non-small cell lung carcinoma.